Mediar Therapeutics
Latest round
- Series B
Last raised
- Dec 2025
Total raised
- $95M
Investors
- 15
About Mediar Therapeutics
Founded in 2018 and based in Massachusetts, US, Mediar Therapeutics, Inc. is a discovery-stage company developing new treatments for fibrosis. The company was founded by Mass General Brigham Ventures. The firm’s foundational technology is based on pioneering research from Massachusetts General Hospital and Brigham and Women's Hospital. In December 2025, Mediar Therapeutics, Inc. The company’s platform and pipeline are based on an emerging class of novel targets, fibrotic mediators that play key roles in modulating myofibroblast biology and the development of fibrosis in chronically damaged organs.
Who invested in Mediar Therapeutics
15 investors across 5 rounds
See all investors in Mediar Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Mediar Therapeutics
Who invested in Mediar Therapeutics?
Mediar Therapeutics has 15 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Mediar Therapeutics raised?
Mediar Therapeutics has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Mediar Therapeutics last raise money?
Mediar Therapeutics's most recent round on record is a Series B, in Dec 2025.
What does Mediar Therapeutics do?
Founded in 2018 and based in Massachusetts, US, Mediar Therapeutics, Inc.
Where is Mediar Therapeutics headquartered?
Mediar Therapeutics is headquartered in Boston, US.
Which VCs invest in companies like Mediar Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Mediar Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Mediar Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.